Back to top
more

Sage Therapeutics (SAGE)

(Delayed Data from NSDQ)

$6.05 USD

6.05
1,060,671

-0.03 (-0.49%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $6.06 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View

by Zacks Equity Research

BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

by Zacks Equity Research

Sage Therapeutics' third-quarter 2024 earnings miss estimates. Stock falls in after-hours trading.

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -0.66% and 7.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?

by Zacks Equity Research

In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Sage Therapeutics (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

by Zacks Equity Research

SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading.

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study

by Zacks Equity Research

The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why

by Zacks Equity Research

The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

by Zacks Equity Research

Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.

Kinjel Shah headshot

Biogen Stock Declines 20.9% Year to Date: Time to Sell?

by Kinjel Shah

BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.

Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Sage Therapeutics (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

by Zacks Equity Research

Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -1.19% and 1.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 21.92% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?

by Zacks Equity Research

Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

by Zacks Equity Research

Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More

by Ekta Bagri

Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

by Zacks Equity Research

Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.

SAGE's Huntington's Disease Study Meets Primary Endpoint

by Zacks Equity Research

The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -10.43% and 28.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?